New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free

Friday, November 13, 2026

Back to the front page

Looking Back at Another Successful Thesis

DoubleU Games raised its all-cash tender offer for DoubleDown Interactive minority holders to $16.25 per ADS from $11.25 after net cash made the earlier bid untenable.

From X

Fajasy on X

Boost Run $BRUN shows $218.6M of new GPU leases in Q3, and its September 30 lease schedule still implies a ~7% interest rate, the same as the June 30 schedule implied. $BRUN had to put $96.0M of its own cash up front on two of the three GPU leases it signed in Q3: → 36-month lease: $59.2M advance, then $2.7M/month. → 24-month lease: $36.8M first payment, then $4.3M/month. For reference, the $59.2M advance alone is more than the $39.4M of advances across all 34 GPU leases $BRUN signed in H1 2026. In Q3, $88.2M of warrant exercises covered most of the $109.8M of lease principal $BRUN paid, and cash still rose $36.9M to $170.0M ($157.0M unrestricted). All 11.4M warrants are now exercised, and GPU lease payments due from January to December 2027 rose to $186.2M as of September 30, from $103.5M as of June 30. The two big Q3 leases alone add $6.9M/month of payments in 2027. The ~$221M of 2027 payments I counted across $BRUN's signed commitments in my October 19 update is now ~$307M, before the five equipment leases $BRUN signed in October, which require $83.1M of payments over the next two years. Four of those five are six-month leases that end with $39.6M of final payments, 59.8% of their $66.2M of total payments. Against those payments, $BRUN says $482M of customer prepayments are due as upcoming projects deploy. So 2027 now runs on (1) those prepayments arriving on schedule and (2) monthly billings, since the warrant cash won't repeat.

Fajasy on X

Boost Run $BRUN just pushed $12.7M/month of revenue from a project at a Georgia data center into Q1 2027, which implies year-end ARR of $283-291M instead of the $400M it expected in August! CFO Erik Guckel said on the Q3 call that $BRUN would've reached $435M of ARR by year-end 2026 without the delay. CEO Andrew Karos blamed a city council request that paused progress at the site, now resolved, and said the project is worth $144-152M of ARR. Q3 revenue came in at $39.9M, up from $31.1M in Q2 but 23.6% below the $52.2M that a straight-line climb to $400M of ARR implied. Year-end ARR would then land right around the $280M in the bear case of my October 19 update. That bear case also had a $62.2M stock sale assumption, which I said on October 26 I'd drop if the 10-Q confirmed $BRUN's $600M+ of project financing. The 10-Q backs up most of the $600M+: $486.9M of new GPU leases through September 30, plus five equipment leases signed in October that require $83.1M of payments. So I'm dropping that stock sale risk, which lifts the bear case to $5.04/share after counting all 6.23M RSUs granted in Q3. At ~$6.20/share, $BRUN trades 23.0% above that bear case. TCV stands at $2.7B, up $800M from Q2, and the 10-Q adds that the agreements signed in September alone are worth more than $700M. Still, the Q3 deck $BRUN released on November 12 says TCV includes renewal options and LOIs, without saying how much of the $2.7B they make up. So I read the miss as timing, not demand: If the Georgia project is billing by March 31, 2027, ARR would clear the $400M in my base case a quarter later than I assumed. The other date to watch is November 30, when the 240 GPU servers from the order $BRUN signed in June are scheduled to start.

Seed Corn

Chiron’s failed $49 million Beaumont sale and $178 million Pinnacle acquisition leave XRN with $70 million of liquidity and medical-office…

Post Q3 EVC Update

EVC's Q3 update cites $30 million for a single station, a broadcast-business sale and stronger positioning for 2027.

Entravision Q3 Update

Entravision’s Q3 ad-tech revenue reached $177.2 million, up 133% year over year, while total revenue rose 88% to $226.3 million and diluted…

KHTRF · long

Knight Therapeutics INC

Knight Therapeutics (GUD-T) is a long position built on confidence in founder Jonathan Goodman, following his earlier success with Paladin…

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.